Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.

Urology

Volumn 63, Issue 3, 2004, Pages

  Raina, Rupesh ^a   Lakin, Milton M ^a   Agarwal, Ashok ^a   Ausmundson, Sandra ^a   Montague, Drogo K ^a   Zippe, Craig D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PIPERAZINE DERIVATIVE; PROSTAGLANDIN E1; SILDENAFIL; VASODILATOR AGENT;

AGED; ARTICLE; FOLLOW UP; HUMAN; IMPOTENCE; INJECTION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PENIS; PROSTATECTOMY; QUESTIONNAIRE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ALPROSTADIL; FOLLOW-UP STUDIES; HUMANS; IMPOTENCE; INJECTIONS; MALE; MIDDLE AGED; PAPAVERINE; PATIENT SATISFACTION; PENIS; PHENTOLAMINE; PIPERAZINES; PROSTATECTOMY; QUESTIONNAIRES; TREATMENT OUTCOME; VASODILATOR AGENTS;

MLCS; MLOWN;

EID: 2942657341     PISSN: None     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2003.10.074     Document Type: Article

References (0)